Literature DB >> 20501838

betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.

Joshua A McCarroll1, Pei Pei Gan, Marjorie Liu, Maria Kavallaris.   

Abstract

Advanced non-small cell lung cancer (NSCLC) has a dismal prognosis. betaIII-Tubulin, a protein highly expressed in neuronal cells, is strongly associated with drug-refractory and aggressive NSCLC. To date, the role of this protein in in vivo drug resistance and tumorigenesis has not been determined. NSCLC cells stably expressing betaIII-tubulin short hairpin RNA displayed reduced growth and increased chemotherapy sensitivity when compared with control clones. In concordance with these results, stable suppression of betaIII-tubulin reduced the incidence and significantly delayed the growth of tumors in mice relative to controls. Our findings indicate that betaIII-tubulin mediates not only drug sensitivity but also the incidence and progression of lung cancer. betaIII-Tubulin is a cellular survival factor that, when suppressed, sensitizes cells to chemotherapy via enhanced apoptosis induction and decreased tumorigenesis. Findings establish that upregulation of a neuronal tubulin isotype is a key contributor to tumor progression and drug sensitivity in lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501838     DOI: 10.1158/0008-5472.CAN-09-4487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Gene expression analysis of SCC tumor cells in muscle tissue.

Authors:  Walter Hundt; Esther L Yuh; Mykhaylo Burbelko; Andreas Kiessling; Mark D Bednarski; Silke Steinbach
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-15       Impact factor: 2.503

2.  Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Authors:  Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T Northcote; Ernest Hamel; Paraskevi Giannakakou; John H Miller
Journal:  Mol Cancer Ther       Date:  2011-06-08       Impact factor: 6.261

3.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Authors:  C M Fife; S M Sagnella; W S Teo; S T Po'uha; F L Byrne; Y Y C Yeap; D C H Ng; T P Davis; J A McCarroll; M Kavallaris
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

Review 4.  Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.

Authors:  Cristina C Rohena; Susan L Mooberry
Journal:  Nat Prod Rep       Date:  2014-03       Impact factor: 13.423

5.  Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Authors:  Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee
Journal:  Invest New Drugs       Date:  2015-12-21       Impact factor: 3.850

Review 6.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

7.  Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue.

Authors:  Suzan K Chao; Yihong Wang; Pascal Verdier-Pinard; Chia-Ping H Yang; Lingling Liu; Alicia Rodriguez-Gabin; Hayley M McDaid; Susan Band Horwitz
Journal:  Cytoskeleton (Hoboken)       Date:  2012-07-02

8.  Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors:  Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal:  Protoplasma       Date:  2016-12-09       Impact factor: 3.356

9.  High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.

Authors:  Yihong Wang; Joseph A Sparano; Susan Fineberg; Lesley Stead; Jaya Sunkara; Susan Band Horwitz; Hayley M McDaid
Journal:  Clin Breast Cancer       Date:  2012-12-06       Impact factor: 3.225

10.  2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes.

Authors:  Chia-Ping Huang Yang; Eng-Hui Yap; Hui Xiao; Andras Fiser; Susan Band Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.